text: contentProstate Cancer: Overview References Thomas, L. The Lives of a Cell, Second Edition 1978. New York: Penguin Books. Bastacky, S.I., Wojno, K.J., Walsh, P.C. et al. Pathological features of hereditary prostate cancer. J. Urol. 1995; 153: 987–92. Carter, B.S., Bova, G.S., Beaty, T.H. et al. Hereditary prostate cancer: epidemiologic and clinical features. J. Urol. 1993; 150: 797–802. Heisey, R.E., Carroll, J.C., Warner, E. et al. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers. Can. Fam. Physician 1999; 45: 114–24. Carter, B.S., Steinberg, G.D., Beaty, T.H. et al. Familial risk factors for prostate cancer. Cancer Surv. 1991; 11: 5–13. Carter, B.S., Beaty, T.H., Steinberg, G.D. et al. Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 3367–71. McWhorter, W.P., Hernandez, A.D., Meikle, A.W. et al. A screening study of prostate cancer in high risk families. J. Urol. 1992; 148: 826–8. Miesfeldt, S., Jones, S.M., Cohn, W. et al. Men's attitudes regarding genetic testing for hereditary prostate cancer risk. Urology 2000; 55: 46–50. Royal, C., Baffoe-Bonnie, A., Kittles, R. et al. Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Ann. Epidemiol. 2000; 10: S68–S77. Sellers, T.A., Potters, L., Rich, S.S. et al. Familial clustering of cancers of the breast and prostate in a population-based sample of postmenopausal women. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1994; 35: A1724. Liede, A., Metcalfe, K., Hanna, D. et al. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am. J. Hum. Genet. 2000; 67: 1494–1504. Fasouliotis, S.J., Schenker, J.G. BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstet. Gynecol. Surv. 2000; 55: 373–84. Heinig, J., Jackisch, C., Rody, A. et al. Clinical management of breast cancer in males: a report of four cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002; 102: 67–73. Gann, P.H., Ma, J., Giovannucci, E. et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999; 59: 1225–30. Giovannucci, E., Ascherio, A., Rimm, E.B. et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl. Cancer Inst. 1995; 87: 1767–76. Gerster, H. The potential role of lycopene for human health. J. Am. Coll. Nutr. 1997; 16: 109–26. Agarwal, S., Rao, A.V. Tomato lycopene and its role in human health and chronic diseases. CMAJ 2000; 163: 739–44. Heber, D., Lu, Q.Y. Overview of mechanisms of action of lycopene. Exp. Biol. Med. 2002; 227: 920–3. Arab, L., Steck, S. Lycopene and cardiovascular disease. Am. J. Clin. Nutr. 2000; 71: 1691S–1695S; discussion, 1696S–1697S. Bosetti, C., Tzonou, A., Lagiou, P. et al. Fraction of prostate cancer incidence attributed to diet in Athens, Greece. Eur. J. Cancer Prev. 2000; 9: 119–23. Clinton, S.K., Emenhiser, C., Schwartz, S.J. et al. cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 823–33. van Breemen, R.B., Xu, X., Viana, M.A. et al. Liquid chromatography-mass spectrometry of cis- and all-trans-lycopene in human serum and prostate tissue after dietary supplementation with tomato sauce. J. Agric. Food Chem. 2002; 50: 2214–9. Giovannucci, E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J. Natl. Cancer Inst. 1999; 91: 317–31. Lu, Q.Y., Hung, J.C., Heber, D. et al. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2001; 10: 749–56. Giovannucci, E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp. Biol. Med. 2002; 227: 852–9. Giovannucci, E., Rimm, E.B., Liu, Y. et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. 2002; 94: 391–8. Blumenfeld, A.J., Fleshner, N., Casselman, B. et al. Nutritional aspects of prostate cancer: a review. Can. J. Urol. 2000; 7: 927–35; discussion, 936. Mucci, L.A., Tamimi, R., Lagiou, P. et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int. 2001; 87: 814–20. Signorello, L.B., Kuper, H., Lagiou, P. et al. Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur. J. Cancer. Prev. 2000; 9: 173–8. Wang, Y., Corr, J.G., Thaler, H.T. et al. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst. 1995; 87: 1456–62. Mukherjee, P., Sotnikov, A.V., Mangian, H.J. et al. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J. Natl. Cancer Inst. 1999; 91: 512–23. Chan, J.M., Stampfer, M.J., Giovannucci, E. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6. Cohen, P., Peehl, D.M., Lamson, G. et al. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. 1991; 73: 401–7. Nakao-Hayashi, J., Ito, H., Kanayasu, T. et al. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992; 92: 141–9. Huynh, H., Seyam, R.M., Brock, G.B. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res. 1998; 58: 215–8. Miyake, H., Hara, I., Yamanaka, K. et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39: 123–9. du Toit, P.J., van Aswegen, C.H., du Plessis, D.J. The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells. Prostaglandins Leukot. Essent. Fatty Acids 1996; 55: 173–7. Sears, B. The Omega Rx Zone: The Miracle of High-Dose Fish Oil, First Edition 2002. New York: HarperCollins. Nie, D., Che, M., Grignon, D. et al. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. 2001; 20: 195–206. Xu, X.C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002; 13: 127–37. Gupta,S., Srivastava, M., Ahmad, N. et al. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001; 91: 737–43. Fujita, H., Koshida, K., Keller, E.T. et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232–40. Attiga, F.A., Fernandez, P.M., Weeraratna, A.T. et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000; 60: 4629–37. Kirschenbaum, A., Liu, X., Yao, S. et al. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58: 127–31. Tjandrawinata, R.R., Dahiya, R., Hughes-Fulford, M. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br. J. Cancer 1997; 75: 1111–8. Ghosh, J., Myers, C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 13182–7. Ghosh, J., Myers, C.E. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. 1997; 235: 418–23. Ghosh, J., Myers, C.E., Jr. Arachidonic acid metabolism and cancer of the prostate. Nutrition 1998; 14: 48–9. Myers, C.E., Ghosh, J. Lipoxygenase inhibition in prostate cancer. Eur. Urol. 1999; 35: 395–8. Barham, J.B., Edens, M.B., Fonteh, A.N. et al. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J. Nutr. 2000; 130: 1925–31. Carollo, M., Parente, L., D'Alessandro, N. Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol. Res. 1998; 10: 245–54. Harvei, S., Bjerve, K.S., Tretli, S. et al. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int. J. Cancer 1997; 71: 545–51. Brooks, J.D., Metter, E.J., Chan, D.W. et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J. Urol. 2001; 166: 2034–8. Duffield-Lillico, A.J., Reid, M.E., Turnbull, B.W. et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev. 2002; 11: 630–9. Clark, L.C., Combs, G.F., Jr., Turnbull, B.W. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276: 1957–63. Venkateswaran, V., Klotz, L.H., Fleshner, N.E. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res. 2002; 62: 2540–5. Vadgama, J.V., Wu, Y., Shen, D. et al. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. 2000; 20: 1391–1414. Helzlsouer, K.J., Huang, H.Y., Alberg, A.J. et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J. Natl. Cancer Inst. 2000; 92: 2018–23. Zhang, Y., Ni, J., Messing, E.M. et al. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc. Natl. Acad. Sci. 2002; 99: 7408–13. Heinonen, O.P., Albanes, D., Virtamo, J. et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 1998; 90: 440–6. Chan, J.M., Stampfer, M.J., Ma, J. et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 893–9. Hirayama, T. A large scale cohort study on cancer risks by diet—with special reference to the risk reducing effects of green-yellow vegetable consumption. Princess Takamatsu Symp. 1985; 16: 41–53. Woodson, K., Triantos, S., Hartman, T. et al. Long-term alpha-tocopherol supplementation is associated with lower serum vascular endothelial growth factor levels. Anticancer Res. 2002; 22: 375–8. Fleshner, N., Fair, W.R., Huryk, R. et al. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J. Urol. 1999; 161: 1651–4. Chan, J.M., Giovannucci, E., Andersson, S.O. et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998; 9: 559–66. Chan, J.M., Stampfer, M.J., Ma, J. et al. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am. J. Clin. Nutr. 2001; 74: 549–54. Giovannucci, E., Rimm, E.B., Wolk, A. et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 1998; 58: 442–7. Stacewicz-Sapuntzakis, M., Bowen, P.E., Hussain, E.A. et al. Chemical composition and potential health effects of prunes: a functional food? Crit. Rev. Food. Sci. Nutr. 2001; 41: 251–86. Patterson, R.E., Neuhouser, M.L., White, E. et al. Cancer-related behavior of vitamin supplement users. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 79–81. Rowling, J.K., Harry Potter and the Goblet of Fire, First Edition 2000, p. 723. New York: Scholastic Press. Peck, S.M. A World Waiting to Be Born. Civility Rediscovered, Second Edition 1997, p. 50. New York: Bantam Books. Gao, X., Mohideen, N., Flanigan, R.C. et al. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. J. Urol. 2000; 164: 1982–6. Narayan, P., Gajendran, V., Taylor, S.P. et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 205–12. Moul, J.W., Connelly, R.R., Perahia, B. et al. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J. Urol. 1998; 159: 935–40. Dattoli, M., Wallner, K., True, L. et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999; 45: 853–6. D'Amico, A.V., Schultz, D., Silver, B. et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 679–84. Haese, A., Graefen, M., Noldus, J. et al. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J. Urol. 1997; 158: 2188–92. D'Amico, A.V., Propert, K.J. Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1996; 35: 273–9. D'Amico, A.V., Whittington, R., Malkowicz, S.B. et al. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology 1998; 52: 631–6. Feneley, M.R., Landis, P., Simon, I. et al. Today men with prostate cancer have larger prostates. Urology 2000; 56: 839–42. Kaminski, J.M., Hanlon, A.L., Horwitz, E.M. et al. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 888–92. Thomas, M.D., Cormack, R., Tempany, C.M. et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 905–8. Rukstalis, D.B., Goldknopf, J.L., Crowley, E.M. et al. Prostate cryoablation: a scientific rationale for future modifications. Urology 2002; 60: 19–25. Merrick, G.S., Butler, W.M., Lief, J.H. et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 121–8. Merrick, G.S., Butler, W.M., Galbreath, R.W. et al. Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy. Urology 2001; 57: 524–9. Steele, G.S., Sullivan, M.P., Sleep, D.J. et al. Combination of symptom score, flow rate and prostate volume for predicting bladder outflow obstruction in men with lower urinary tract symptoms. J. Urol. 2000; 164: 344–8. Wang, H., Wallner, K., Sutlief, S. et al. Transperineal brachytherapy in patients with large prostate glands. Int. J. Cancer 2000; 90: 199–205. Daniell, H.W. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58: 101–7. Neugut, A.I., Rosenberg, D.J., Ahsan, H. et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 869–73. Johnstone, P.A., Powell, C.R., Riffenburgh, R. et al. Second primary malignancies in T1-3N0 prostate cancer patients treated with radiation therapy with 10-year followup. J. Urol. 1998; 159: 946–9. Vollmer, R.T., Egawa, S., Kuwao, S. et al. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer 2002; 94: 1692–8. Arai, Y., Egawa, S., Kuwao, S. et al. The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting. BJU Int. 2001; 88: 909–14. Borre, M., Offersen, B.V., Nerstrom, B. et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer 1998; 78: 940–4. Borre, M., Stausbol-Gron, B., Overgaard, J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J. Urol. 2000; 164: 716–21. Borre, M., Nerstrom, B., Overgaard, J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res. 2000; 6: 1882–90. Choo, R., Klotz, L., Danjoux, C. et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 2002; 167: 1664–9. McLaren, D.B., McKenzie, M., Duncan, G. et al. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998; 82: 342–8. Begg, C.B., Riedel, E.R., Bach, P.B. et al. Variations in morbidity after radical prostatectomy. N. Engl. J. Med. 2002; 346: 1138–44. Noldus, J., Michl, U., Graefen, M. et al. Nerve-sparing radical retropubic prostatectomy. Results of a patient survey. Urologe A 2001; 40: 102–6. Keetch, D.W., McMurtry, J.M., Smith, D.S. et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J. Urol. 1996; 156: 428–31. Maeda, H., Arai, Y., Okubo, K. et al. Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients. Int. J. Urol. 1998; 5: 343–8. Chakrabarti, S., Raha, K., Bhunia, C.L. et al. The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma. J. Indian Med. Assoc. 2001; 99: 627–8, 630. Oesterling, J.E., Brendler, C.B., Epstein, J.I. et al. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J. Urol. 1987; 138: 92–8. Partin, A.W., Yoo, J., Carter, H.B. et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. 1993; 150: 110–4. McNeal, J.E. The zonal anatomy of the prostate. Prostate 1981; 2: 35–49. Lee, F., Torp-Pedersen, S.T., Siders, D.B. et al. The use of transrectal ultrasound in the study of normal and abnormal anatomy of the prostate gland. In Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, First Edition, 1989, pp. 23–36. Labrie, F., Dupont, A., Lee, F., Eds. Amsterdam: Elsevier Science. Djavan, B., Remzi, M., Zlotta, A.R. et al. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech. Urol. 1999; 5: 71–6. Djavan, B., Zlotta, A., Kratzik, C. et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999; 54: 517–22. Djavan, B., Zlotta, A.R., Remzi, M. et al. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology 1999; 54: 846–52. Carter, H.B., Pearson, J.D. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol. Clin. North Am. 1997; 24: 333–8. Barak, M., Cohen, M., Mecz, Y. et al. The additional value of free prostate specific antigen to the battery of age-dependent prostate-specific antigen, prostate-specific antigen density and velocity. Eur. J. Clin. Chem. Clin. Biochem. 1997; 35: 475–81. Vollmer, R.T., Dawson, N.A., Vogelzang, N.J. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer 1998; 83: 1989–94. Carter, H.B., Pearson, J.D., Waclawiw, Z. et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45: 591–6. Kadmon, D., Weinberg, A.D., Williams, R.H. et al. Pitfalls in interpreting prostate specific antigen velocity. J. Urol. 1996; 155: 1655–7. Carter, H.B., Pearson, J.D. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol. Clin. North Am. 1993; 20: 665–70. Egawa, S., Suyama, K., Takashima, R. et al. Prospective evaluation of prostate cancer detection by prostate-specific antigen-related parameters. Int. J. Urol. 1999; 6: 493–501. Hanks, G.E., Hanlon, A.L., Lee, W.R. et al. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int. J. Radiat. Oncol. Biol. Phys. 1996; 34: 549–53. Stephenson, A.J., Aprikian, A.G., Souhami, L. et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59: 652–6. Fowler, J.E., Jr., Pandey, P., Seaver, L.E. et al. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J. Urol. 1995; 153: 1860–5. Pollack, A., Zagars, G.K., el-Naggar, A.K. et al. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 1994; 44: 711–8. Hanlon, A.L., Diratzouian, H., Hanks, G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002 Jun 1; 53(2): 297–303. Lee, W.R., Hanks, G.E., Hanlon, A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J. Clin. Oncol. 1997; 15: 230–8. Roberts, S.G., Blute, M.L., Bergstralh, E.J. et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin. Proc. 2001; 76: 576–81. Zagars, G.K., Pollack, A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother. Oncol. 1997; 44: 213–21. Tarle, M., Frkovic-Grazio, S., Kraljic, I. et al. A more objective staging of advanced prostate cancer—routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values. Prostate 1994; 24: 143–8. Tarle, M., Rados, N. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate 1991; 19: 23–33. Aihara, M., Lebovitz, R.M., Wheeler, T.M. et al. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J. Urol. 1994; 151: 1558–64. Bidart, J.M., Thuillier, F., Augereau, C. et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin. Chem. 1999; 45: 1695–1707. Oremek, G.M., Seiffert, U.B. Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. Clin. Chem. 1996; 42: 691–5. Leventhal, E.K., Rozanski, T.A., Morey, A.F. et al. The effects of exercise and activity on serum prostate specific antigen levels. J. Urol. 1993; 150: 893–4. Piironen, T., Nurmi, M., Irjala, K. et al. Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing. Clin. Chem. 2001; 47: 703–11. Tchetgen, M.B., Song, J.T., Strawderman, M. et al. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47: 511–6. Crawford, E.D., Chia, D., Andriole, G. et al. PSA changes as related to the initial PSA: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Proc. Am. Soc. Clin. Oncol. 2001; 20: 177a. Harris, C.H., Dalkin, B.L., Martin, E. et al. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/mL or less. J. Urol. 1997; 157: 1740–3. Fowler, J.E., Jr., Bigler, S.A., Miles, D. et al. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J. Urol. 2000; 163: 813–8. Catalona, W.J., Partin, A.W., Finlay, J.A. et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999; 54: 220–4. Stephan, C., Jung, K., Cammann, H. et al. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation. Int. J. Cancer 2002; 99: 466–73. Chen, Y.T., Luderer, A.A., Thiel, R.P. et al. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 518–24. Carter, H.B., Morrell, C.H., Pearson, J.D. et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992; 52: 3323–8. Lujan, M., Paez, A., Sanchez, E. et al. Prostate specific antigen variation in patients without clinically evident prostate cancer. J. Urol. 1999; 162: 1311–3. Ciatto, S., Bonardi, R., Lombardi, C. et al. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. Int. J. Biol. Markers 2002; 17: 79–83. Imai, K., Ichinose, Y., Kubota, Y. et al. Clinical significance of prostate specific antigen for early stage prostate cancer detection. Jpn. J. Clin. Oncol. 1994; 24: 160–5. Larson, T.R., Robertson, D.W., Corica, A. et al. In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology 2000; 55: 547–52. Goldstein, N.S., Kestin, L.L., Vicini, F.A. et al. The influence of percentage of pre-radiation needle biopsies with adenocarcinoma and total radiation dose on the pathologic response of unfavorable prostate adenocarcinoma. Am. J. Clin. Pathol. 2002; 117: 927–34. Lankford, S.P., Pollack, A., Zagars, G.K. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1997; 38: 327–33. Schulte, R.W., Slater, J.D., Rossi, C.J., Jr. et al. Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther. Onkol. 2000; 176: 3–8. Rossi, C.J., Jr., Slater, J.D., Reyes-Molyneux, N. et al. Particle beam radiation therapy in prostate cancer: is there an advantage? Semin. Radiat. Oncol. 1998; 8: 115–23. Laramore, G.E., Krall, J.M., Thomas, F.J. et al. Fast neutron radiotherapy for locally advanced prostate cancer: results of an RTOG randomized study. Int. J. Radiat. Oncol. Biol. Phys. 1985; 11: 1621–7. Molls, M., Stadler, P., Becker, A. et al. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther. Onkol. 174(Suppl. 4): 13–6. Stadler, P., Becker, A., Feldmann, H.J. et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44: 749–54. Dennis, L.K., Lynch, C.F., Torner, J.C. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78–83. Nelson, W.G., De Marzo, A.M., Deweese, T.L. et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann. N.Y. Acad. Sci. 2001; 952: 135–44. Orozco, R., O'Dowd, G., Kunnel, B. et al. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology 1998; 51: 186–95. Han, M., Snow, P.B., Epstein, J.I. et al. A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 2000; 56: 994–9. Sakr, W.A., Tefilli, M.V., Grignon, D.J. et al. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000; 56: 730–4. Chan, T.Y., Partin, A.W., Walsh, P.C. et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56: 823–7. Partin, A.W., Mangold, L.A., Lamm, D.M. et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843–8. D'Amico, A.V., Whittington, R., Malkowicz, S.B. et al. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 194; 30: 293–302. Carlson, G.D., Calvanese, C.B., Partin, A.W. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998; 52: 455–61. Badalament, R.A., Miller, M.C., Peller, P.A. et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J. Urol. 1996; 156: 1375–80. Partin, A.W., Kattan, M.W., Subong, E.N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–51. Kattan, M.W., Wheeler, T.M., Scardino, P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 1999; 17: 1499–1507. Kattan, M.W., Zelefsky, M.J., Kupelian, P.A. et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. 2000; 18: 3352–9. Kattan, M.W., Potters, L., Blasko, J.C. et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001; 58: 393–9. Bluestein, D.L., Bostwick, D.G., Bergstralh, E.J. et al. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol. 1994; 151: 1315–20. Gilliland, F.D., Hoffman, R.M., Hamilton, A. et al. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study. J. Urol. 1999; 162: 1341–5. Lerner, S.E., Blute, M.L., Bergstralh, E.J. et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J. Urol. 1996; 156: 137–43. Pisansky, T.M., Kozelsky, T.F., Myers, R.P. et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J. Urol. 2000; 163: 845–50. Gamito, E.J., Stone, N.N., Batuello, J.T. et al. Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy. Tech. Urol. 2000; 6: 60–3. Stephan, C., Cammann, H., Semjonow, A. et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin. Chem. 2002; 48: 1279–87. Ogawa, O., Egawa, S., Arai, Y. et al. Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer. Int. J. Urol. 1998; 5: 454–8. Ziada, A.M., Lisle, T.C., Snow, P.B. et al. Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. Cancer 2001; 91: 1653–60. Tewari, A., Porter, C., Peabody, J. et al. Predictive modeling techniques in prostate cancer. Mol. Urol. 2001; 5: 147–52. Errejon, A., Crawford, E.D., Dayhoff, J. et al. Use of artificial neural networks in prostate cancer. Mol. Urol. 2001; 5: 153–8. Porter, C., O'Donnell, C., Crawford, E.D. et al. Artificial neural network model to predict biochemical failure after radical prostatectomy. Mol. Urol. 2001; 5: 159–62. Tewari, A., Issa, M., El-Galley, R. et al. Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol. Urol. 2001; 5: 163–9. Babaian, R.J., Fritsche, H., Ayala, A. et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 2000; 56: 1000–6. Blute, M.L., Bergstralh, E.J., Iocca, A. et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 2001; 165: 119–25. Conrad, S., Graefen, M., Pichlmeier, U. et al. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J. Urol. 1998; 159: 2023–9. Batuello, J.T., Gamito, E.J., Crawford, E.D. et al. Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology 2001; 57: 481–5. Long, J.P., Bahn, D., Lee, F. et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001; 57: 518–23. Critz, F.A., Williams, W.H., Levinson, A.K. et al. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J. Urol. 2000; 164: 738–41; discussion, 741–3. Blasko, J.C., Grimm, P.D., Sylvester, J.E. et al. Palladium-103 brachytherapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2000; 46: 839–50. Onik, G. Cryosurgery. Crit. Rev. Oncol. Hematol. 1996; 23: 1–24. Cohen, J.K., Miller, R.J., Rooker, G.M. et al. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Urology 1996; 47: 395–401. Tatsutani, K., Rubinsky, B., Onik, G. et al. Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology 1996; 48: 441–7. Lee, F., Bahn, D.K., McHugh, T.A. et al. Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring—a one year follow-up. Anticancer Res. 1997; 17: 1511–5. Ghafar, M.A., Johnson, C.W., De La Taille, A. et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J. Urol. 2001; 166: 1333–7; discussion, 1337–8. de la Taille, A., Benson, M.C., Bagiella, E. et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000; 85: 281–6. Onik, G. Image-guided prostate cryosurgery: state of the art. Cancer Control 2001; 8: 522–31. Zisman, A., Pantuck, A.J., Cohen, J.K. et al. Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology 2001; 58: 988–93. Dillioglugil, O., Leibman, B.D., Leibman, N.S. et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J. Urol. 1997; 157: 1760–7. Albertsen, P.C., Fryback, D.G., Storer, B.E. et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J. Urol. 1996; 156: 127–32. Haban, P., Simoncic, R., Zidekova, E. et al. Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome. Med. Sci. Monit. 2002; 8: CR175–CR179. Bhatti, M.S., Akbri, M.Z., Shakoor, M. Lipid profile in obesity. J. Ayub Med. Coll. Abbottabad 2001; 13: 31–3. Park, R., Detrano, R., Xiang, M. et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation 2002; 106: 2073–7. Speidl, W.S., Graf, S., Hornykewycz, S. et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am. Heart J. 2002; 144: 449–55. Albert, C.M., Ma, J., Rifai, N. et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595–9. Mayser, P., Mayer, K., Mahloudjian, M. et al. A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. J. Parenter. Enteral. Nutr. 2002; 26: 151–8. Dewailly, E.E., Blanchet, C., Gingras, S. et al. Relations between n-3 fatty acid status and cardiovascular disease risk factors among Quebecers. Am. J. Clin. Nutr. 2001; 74: 603–11. Watkins, B.A., Li, Y., Allen, K.G. et al. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J. Nutr. 2000; 130: 2274–84. Adams, P.B., Lawson, S., Sanigorski, A. et al. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996; 31(Suppl.): S157–S161. Frost, R. Fire and Ice. In The Poetry of Robert Frost 1975, p. 220, Lathem, E.C., Ed. New York: Holt, Rinehart and Winston. Barry, M.J., Fowler, F.J., Jr., O'Leary, M.P. et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 1992; 148: 1549–57; discussion, 1564. Park, R., Martin, S., Goldberg, J.D. et al. Anastomotic strictures following radical prostatectomy: insights into incidence, effectiveness of intervention, effect on continence, and factors predisposing to occurrence. Urology 2001; 57: 742–6. Han, M., Piantadosi, S., Zahurak, M.L. et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 2001; 57: 707–11. Webber, M.M., Waghray, A., Bello, D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1995; 1: 1089–94. Kennedy-Smith, A.G., McKenzie, J.L., Owen, M.C. et al. Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J. Urol. 2002; 168: 741–7. Lee, C., Sintich, S.M., Mathews, E.P. et al. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999; 39: 285–90. Webber, M.M., Waghray, A. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin. Cancer Res. 1995; 1: 755–61. Shariat, S.F., Shalev, M., Menesses-Diaz, A. et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 2001; 19: 2856–64. Zelefsky, M.J., Lyass, O., Fuks, Z. et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J. Clin. Oncol. 1998; 16: 3380–5. Strum, S.B., Scholz, M.C., McDermed, J.E. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2000; 5: 45–52. Szostak, M.J., Kaur, P., Amin, P. et al. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J. Urol. 2001; 165: 2126–30. Huang, A., Gandour-Edwards, R., Rosenthal, S.A. et al. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 1998; 51: 346–51. Scherr, D.S., Vaughan, E.D., Jr., Wei, J. et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J. Urol. 1999; 162: 12–6; discussion, 16–7. Rakozy, C., Grignon, D.J., Sarkar, F.H. et al. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Mod. Pathol. 1998; 11: 892–9. Häggström, S., Lissbrant, I.F., Bergh, A. et al. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J. Urol. 1999; 161: 1620–5. Cawley, H.M., Meltzer, S.J., De Benedetti, V.M. et al. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998; 115: 19–27. Smith, C.A., Pollice, A.A., Gu, L.P. et al. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin. Cancer Res. 2000; 6: 112–26. Hughes-Fulford, M., Chen, Y., Tjandrawinata, R.R. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 2001; 22: 701–7. Rose, D.P. Dietary fatty acids and prevention of hormone-responsive cancer. Proc. Soc. Exp. Biol. Med. 1997; 216: 224–33. North, G.L. Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann. Pharmacother. 2001; 35: 1638–43. Zhao, J., Sharma, Y., Agarwal, R. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. Mol. Carcinog. 1999; 26: 321–33. Kelavkar, U.P., Cohen, C., Kamitani, H. et al. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 2000; 21: 1777–87. Stojdl, D.F., Lichty, B., Knowles, S. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000; 6: 821–5. Balachandran, S., Barber, G.N. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000; 50: 135–8. Balachandran, S., Porosnicu, M., Barber, G.N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, ras, or myc function and involves the induction of apoptosis. J. Virol. 2001; 75: 3474–9. Rajan, P., Swaminathan, S., Zhu, J. et al. A novel translational regulation function for the simian virus 40 large-T antigen gene. J. Virol. 1995; 69: 785–95. Randazzo, B.P., Tal-Singer, R., Zabolotny, J.M. et al. Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40. J. Gen. Virol. 1997; 78: 3333–9. Reid, T.M., Loeb, L.A. Mutagenic specificity of oxygen radicals produced by human leukemia cells. Cancer Res. 1992; 52: 1082–6. Macmillan-Crow, L.A., Cruthirds, D.L. Invited review: manganese superoxide dismutase in disease. Free Radic. Res. 2001; 34: 325–36. Sigala, S., Tognazzi, N., Rizzetti, M.C. et al. Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. Eur. J. Endocrinol. 2002; 147: 407–15. Wouters, B.G., Weppler, S.A., Koritzinsky, M. et al. Hypoxia as a target for combined modality treatments. Eur. J. Cancer 2002; 38: 240–57. Leith, J.T., Cook, S., Chougule, P. et al. Intrinsic and extrinsic characteristics of human tumors relevant to radiosurgery: comparative cellular radiosensitivity and hypoxic percentages. Acta Neurochir. Suppl. 1994; 62: 18–27. Dachs, G.U., Dougherty, G.J., Stratford, I.J. et al. Targeting gene therapy to cancer: a review. Oncol. Res. 1997; 9: 313–25. Fosslien, E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci. 2001; 31: 325–48. Liu, X.H., Kirschenbaum, A., Yao, S. et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 2000; 164: 820–5. Stewart, R.J., Panigrahy, D., Flynn, E. et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol. 2001; 165: 688–93. Levine, A.C., Liu, X.H., Greenberg, P.D. et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 1998; 139: 4672–8. 241. Keledjian, K., Borkowski, A., Kim, G. et al. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 2001; 48: 71–8. Joseph, I.B., Isaacs, J.T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst. 1998; 90: 1648–53. Joseph, I.B., Vukanovic, J., Isaacs, J.T. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 1996; 56: 3404–8. Khalil, A., Tullus, K., Bakhiet, M. et al. Angiotensin II type 1 receptor antagonist (losartan) down-regulates transforming growth factor-beta in experimental acute pyelonephritis. J. Urol. 2000; 164: 186–91. Selzer, M.G., Zhu, B., Block, N.L. et al. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann. N.Y. Acad. Sci. 1999; 878: 678–82. Lokeshwar, B.L., Selzer, M.G., Zhu, B.Q. et al. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int. J. Cancer 2002; 98: 297–309. Paget, S. Distribution of secondary growths in cancer of the breast. Lancet 1989; 1: 571–3. Smith, M.R., McGovern, F.J., Fallon, M.A. et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001; 91: 2238–45. Strum, S.B., Scholz, M.C. Quantitative computerized tomography in prostate cancer. J. Urol. 2003 (submitted). Bolotin, H.H. Inaccuracies inherent in dual-energy X-ray absorptiometry in vivo bone mineral densitometry may flaw osteopenic/osteoporotic interpretations and mislead assessment of antiresorptive therapy effectiveness. Bone 2001; 28: 548–55. Frahm, C., Link, J., Hakelberg, K. et al. Densitometry in suspected preclinical osteoporosis: quantitative computerized tomography versus dual energy roentgen absorptiometry. Bildgebung 1994; 61: 256–62. von Stremple, A., Prokopp, M., Flindt, C. A comparison of two noninvasive measurement methods for determining central osteoporosis taking into consideration the ash content. Aktuelle Radiol. 1993; 3: 31–6. Meirelles, E.S., Borelli, A., Camargo, O.P. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin. Rheumatol. 1999; 18: 364–8. von der Recke, P., Hansen, M.A., Overgaard, K. et al. The impact of degenerative conditions in the spine on bone mineral density and fracture risk prediction. Osteoporos. Int. 1996; 6: 43–9. Tremollieres, F., Pouilles, J.M., Ribot, C. Screening techniques. Presse Med. 2002; 31: 694–8. Trivedi, D.P., Khaw, K.T. Bone mineral density at the hip predicts mortality in elderly men. Osteoporos. Int. 2001; 12: 259–65. Thorsen, K., Nordstrom, P., Lorentzon, R. et al. The relation between bone mineral density, insulin-like growth factor I, lipoprotein (a), body composition, and muscle strength in adolescent males. J. Clin. Endocrinol. Metab. 1999; 84: 3025–9. Prie, D., Huart, V., Bakouh, N. et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N. Engl. J. Med. 2002; 347: 983–91. Pak, C.Y., Peterson, R.D., Poindexter, J. Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. J. Urol. 2002; 168: 31–4. Yasui, T., Fujita, K., Sasaki, S. et al. Alendronate inhibits osteopontin expression enhanced by parathyroid hormone-related peptide (PTHrP) in the rat kidney. Urol. Res. 1998; 26: 355–60. Cappuccio, F.P., Kalaitzidis, R., Duneclift, S. et al. Unraveling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J. Nephrol. 2000; 13: 169–77. Siegall, C.B., Schwab, G., Nordan, R.P. et al. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res. 1990; 50: 7786–8. Borsellino, N., Belldegrun, A., Bonavida, B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995; 55: 4633–9. Wise, G.J., Marella, V.K., Talluri, G. et al. Cytokine variations in patients with hormone treated prostate cancer. J. Urol. 2000; 164: 722–5. Garcia-Moreno, C., Mendez-Davila, C., de La Piedra, C. et al. Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 2002; 50: 241–6. Liu, X.H., Kirschenbaum, A., Lu, M. et al. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem. Biophys. Res. Commun. 2002; 290: 249–55. Spiotto, M.T., Chung, T.D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000; 42: 186–95. Coukell, A.J., Markham, A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 1998; 12: 149–68. Blumsohn, A., Herrington, K., Hannon, R.A. et al. The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endocrinol. Metab. 1994; 79: 730–5. Gross, C., Stamey, T., Hancock, S. et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 1998; 159: 2035–9; discussion, 2039–40. Beer, T.M., Munar, M., Henner, W.D. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001; 91: 2431–9. Beer, T.M., Filers, K.M., Garzotto, M. et al. Androgen-independent prostate cancer (AIPC) treatment with weekly high-dose calcitriol and docetaxel. Proc. Am. Soc. Clin. Oncol. 2002; 21: 177a. Nijs, H.G., Essink-Bot, M.L., DeKoning, H.J. et al. Why do men refuse to attend population-based screening for prostate cancer? J. Public Health Med. 2000; 22: 312–6. Webb, J.A., Shanmuganathan, K., McLean, A. Complications of ultrasound-guided transperineal prostate biopsy. A prospective study. Br. J. Urol. 1993; 72: 775–7. Lujan Galan, M., Paez Borda, A., Fernandez Gonzalez, I. et al. Adverse effects of transrectal prostatic biopsy. Analysis of 303 procedures. Actas Urol. Esp. 2001; 25: 46–9. Kearney, M.C., Bingham, J.B., Bergland, R. et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J. Urol. 2002; 167: 2489–91. Sordello, S., Bertrand, N., Plouet, J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem. Biophys. Res. Commun. 1998; 251: 287–90. Haggstrom, S., Torring, N., Moller, K. et al. Effects of finasteride on vascular endothelial growth factor. Scand. J. Urol. Nephrol. 2002; 36: 182–7. Costa, C., Soares, R., Reis-Filho, J.S. et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J. Clin. Pathol. 2002; 55: 429–34. Kaji, Y., Kurhanewicz, J., Hricak, H. et al. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 1998; 206: 785–90. Davis, M., Sofer, M., Kim, S.S. et al. The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J. Urol. 2002; 167: 566–70. Shandera, K.C., Thibault, G.P., Deshon, G.E., Jr. Efficacy of one dose fluoroquinolone before prostate biopsy. Urology 1998; 52: 641–3. Aron, M., Rajeev, T.P., Gupta, N.P. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000; 85: 682–5. Pareek, G., Armenakas, N.A., Fracchia, J.A. Periprostatic nerve blockade for transrectal ultrasound guided biopsy of the prostate: a randomized, double-blind, placebo controlled study. J. Urol. 2001; 166: 894–7. Nash, P.A., Bruce, J.E., Indudhara, R. et al. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J. Urol. 1996; 155: 607–9. Lynn, N.N., Collins, G.N., Brown, S.C. et al. Periprostatic nerve block gives better analgesia for prostatic biopsy. BJU Int. 2002; 90: 424–6. Soloway, M.S., Obek, C. Periprostatic local anesthesia before ultrasound guided prostate biopsy. J. Urol. 2000; 163: 172–3. Alavi, A.S., Soloway, M.S., Vaidya, A. et al. Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods. J. Urol. 2001; 166: 1343–5. Saad, F., Sabbagh, R., McCormack, M. et al. A prospective randomized trial comparing lidocaine and lubrificating gel on pain level in patients undergoing transrectal ultrasound prostate biopsy. Can. J. Urol. 2002; 9: 1592–4. Issa, M.M., Bux, S., Chun, T. et al. A randomized prospective trial of intrarectal lidocaine for pain control during transrectal prostate biopsy: the Emory University experience. J. Urol. 2002; 164: 397–9. Masood, J., Shah, N., Lane, T. et al. Nitrous oxide (Entonox) inhalation and tolerance of transrectal ultrasound guided prostate biopsy: a double-blind randomized controlled study. J. Urol. 2002; 168: 116–20; discussion, 120. Irani, J., Fournier, F., Bon, D. et al. Patient tolerance of transrectal ultrasound-guided biopsy of the prostate. Br. J. Urol. 1997; 79: 608–10. Monti, S., Sciarra, F., Adamo, M.V. et al. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide. J. Androl. 1997; 18: 488–94. Laroque, P.A., Prahalada, S., Molon-Noblot, S. et al. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. Prostate 1995; 27: 121–8. Saez, C., Gonzalez-Baena, A.C., Japon, M.A. et al. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 1999; 40: 83–8. Wang, L.G., Liu, X.M., Kreis, W. et al. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res. 1997; 57: 714–9. Glassman, D.T., Chon, J.K., Borkowski, A. et al. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 2001; 46: 45–51. Ng, Y.K., Bales, W., Box, E. et al. Cardura induced apoptosis in prostate cancer cells in vitro. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1997; 38: A615. Chon, J.K., Borkowski, A., Partin, A.W. et al. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J. Urol. 1999; 161: 2002–8. Benning, C.M., Kyprianou, N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res. 2002; 62: 597–602. Kyprianou, N., Benning, C.M. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000; 60: 4550–5. Cuellar, D.C., Rhee, J., Kyprianou, N. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Anticancer Res. 2002; 22: 1673–9. Huncharek, M., Muscat, J. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Abdom. Imaging 1996; 21: 364–7. Huncharek, M., Muscat, J. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest. 1995; 13: 31–5. Chybowski, F.M., Keller, J.J., Bergstralh, E.J. et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol. 1991; 145: 313–8. Oesterling, J.E., Martin, S.K., Bergstralh, E.J. et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57–60. Sciarra, F., Sorcini, G., Di Silverio, F. et al. Plasma testosterone and androstenedione after orchiectomy in prostatic adenocarcinoma. Clin. Endocrinol. 1973; 2: 101–9. Gibson, C.H. A concept analysis of empowerment. J. Adv. Nurs. 1991; 16: 354–61. Davison, B.J., Degner, L.F. Empowerment of men newly diagnosed with prostate cancer. Cancer Nurs. 1997; 20: 187–96. Jones, P.S., Meleis, A.I. Health is empowerment. Adv Nurs. Sci. 1993; 15: 1–14.


text:
Essential Reads
Essential Reads is your one-stop source for the top stories of the day as reported by your favorite Washington Week panelists. It's a simple way to save time and stay informed about the news you need to know. Check it out every day!
Oct 03, 2012
In 90-minute debate, 2 candidates stand on equal footingBy Jeff Zeleny, The New York Times
President Obama will have the first word at the presidential debate. Mitt Romney will have the last word. But even before they step onto the stage and shake hands here Wednesday evening, voters across the country are already starting to have the final word.Read more
The only debate question that mattersBy Jim Tankersley, National Journal
There are plenty of important questions Jim Lehrer should ask Barack Obama and Mitt Romney during Wednesday night's first presidential debate, but only one Big Question. Lehrer should keep asking it until he gets a real answer, even if it takes all 90 minutes.Read more from National Journal
Claims likely to surface in debate and facts behind themBy Jackie Calmes and John Harwood, The New York Times
The first presidential debate is likely to focus on economic issues as President Obama and Mitt Romney clash over the size and role of government. Here are some topics that could come up.Read more
How campaigning for president became a socially acceptable thing to doBy John Dickerson, Slate Magazine
In the early days of the presidency, no man worthy of the office would have dared campaign for it. Now, as I write in my series How to Measure for a President, the strength of a candidate's campaign is used as proof of his fitness for office. Here, with the help of Gil Troy's See How They Ran is a tour of how we got here.Read more
Republicans face voter ID law setbackBy Pete Williams, NBC News
Oct 02, 2012
Before debate, Romney calls Obama weak on foreign policyBy Sam Youngman, Reuters
Republican presidential challenger Mitt Romney launched a fresh attempt on Monday to paint President Barack Obama as weak on foreign policy, saying he had let U.S. leadership atrophy, while the two candidates prepared for their critical first debate on Wednesday.Read more
10 quotes that haunt President ObamaBy John F. Harris and James Hohmann, Politico
Ahead in the polls, looking strong in key swing states: This must be exactly what Barack Obama dreamed his reelection campaign would look like, five weeks from Election Day and on the eve of the first debate.Read more
Analysis: Will the debates make a difference?By Amy Walter and Michael Falcone, ABC News
Last week Mitt Romney opened an Ohio bus tour on the same day that a new poll in the state showed him lagging behind President Obama by a 10 point margin.Read more
Campaigns search for elusive early votersWith Laura Meckler, Wall Street Journal
With early voting under way in Iowa and about to begin in Ohio, the voters the two presidential campaigns are working hardest to motivate are a challenging group: those least likely to vote in the first place. Laura Meckler has details on The News Hub.
Report: Nearly 90 percent of Americans would see taxes rise if 'fiscal cliff' hitsBy Lori Montgomery, The Washington Post
Nearly 90 percent of Americans would face higher taxes next year if Congress lets the nation hurtle over the "fiscal cliff," the year-end precipice of tax hikes and spending cuts that threatens to throw the nation back into recession.Read more
Oct 01, 2012
Gwen Ifill debunks five myths about presidential debatesBy Gwen Ifill for The Washington Post
As President Obama and Mitt Romney take the stage in Denver on Wednesday for the first of their three debates, they won't just face off against each other. They'll also be competing with the rich history of presidential debates — the zingers, questions and comebacks that will be replayed and invoked over and over in the coming weeks. I've had the privilege to moderate the two most recent vice presidential debates, and I've heard many misconceptions about these events and their impact on a race. Here are a few of the most common.Read more
Obama, Romney in tight race nationally as first debate loomsBy Dan Balz, The Washington Post
On the eve of their first presidential debate, President Obama leads or is at parity with Mitt Romney on virtually every major issue and attribute in what remains a competitive general election, according to a new Washington Post-ABC News poll.Read more
What Obama must (not) do in the debateBy Alexis Simendinger, Real Clear Politics
As President Obama heads into the first of three debates with Mitt Romney nursing a slight lead in the polls, he has a wealth of historic precedent to draw on, and no shortage of advice -- much of it unsolicited -- to guide him.Read more
Debates can shift a race's outcome, but it's not easyBy John Harwood, The New York Times
History shows that candidates have different ways to score through presidential debates: the forceful put-down, the surprising show of skill, the opponent's fumble, superior post-debate tactics.Read more
Romney faces a formidable gender gapBy Beth Reinhard, National Journal
What do women want? Another four years of President Obama, according to a new YWCA-sponsored poll that found him leading Republican Mitt Romney by 49 percent to 31 percent. The yawning gender gap mirrors other surveys nationwide and here in Ohio, a hotly contested swing state, and it represents one of Romney's most pressing challenges in the home stretch before the Nov. 6 election.Read more from National Journal
The prophets of budget balancingBy Doyle McManus, Los Angeles Times
Here's one thing the two presidential candidates agree on: the federal government's current fiscal course will lead to disaster.Read more
Sep 28, 2012
September, November: 40 precious days to spend on early voteBy Jeff Zeleny, The New York Times
A stream of voters arrived at election offices across Iowa to cast their ballots. Waves of absentee ballots have started landing in mailboxes in 30 other states. And more than a month before what the calendar says is Election Day, President Obama began delivering his closing argument to voters.Read more
Pray for rainBy Jim Tankersley, National Journal
The weather forecast could have a big effect on America's economic forecast next year. The more rain, the better.Read more from National Journal
In Virginia, nominees reach out to militaryBy Helene Cooper and Ashley Parke
In case anyone is wondering, Virginia is up for grabs this election. So, with 39 days to go, President Obama and Mitt Romney dueled in the commonwealth on Thursday, both trying to lock up support from voters with ties to the military.Read more
A Rove 'money bomb'?By Doyle McManus, Los Angeles Times
Here's a short list of Democrats who secretly hope Mitt Romney gets his presidential campaign turned around fast and gives President Obama a run for his money: Heidi Heitkamp, the Democratic Senate candidate in North Dakota; Jon Tester, the Democratic senator from Montana; and Rep. Shelley Berkley, the Democratic Senate candidate in Nevada.Read more

subset: commoncrawl


text:
If churches are supposed to help people, why is the City of Houston telling a Southwest Houston church to stop?
The city said the homeless staying in New Deliverance Church have to go because it is not safe. The 29 residents said they have lived in plenty of unsafe environments and the church is not one of them.
"It's not Hyatt. It's not even Motel 6, but it's home," Pastor Janice Caslin said.
Clyde Thompson said he found a miracle at the church.
"This is the first time I've ever got out of prison and I've been clean and sober. I've been out for a year. Normally as soon as I get out, the first thing I do is go get high," Thompson said.
The 60-year-old said this is the longest he has been sober in nearly 40 years. Since 1974, he has been in and out of prison because of drugs. He said he has tried other shelters and programs, but there is something about being in New Deliverance that has saved him from himself.
"People don't understand this. It's going to be hard because I need this. I really need this but they don't care about us. We're all supposed to be the same. We're all supposed to be as one but we are not, not when you're trying to take my home from me," Thompson said as tears streamed down his face.
"I like it here. I'm comfortable here. My kids are comfortable here. They're breaking up a family. They may not think that, but we're all a family," 24-year-old Jessica Bormann said.
Bormann grew up in foster homes and has lived on the street. She and her two girls now live at the church.
"I'm content here. I feel love that I haven't felt before," she said.
Pastor Caslin said she has been taking in the homeless here in her church since 1993.
Less than two months ago, the City of Houston informed her she needed to tag the fire extinguishers, have working exit lights, put in a vent hood over the stove and get a plumber to check for gas leaks. As she made the changes, the city stopped by again.
"… Gave me papers saying they wanted the men to leave immediately and we need to put in a sprinkler system in the sleeping area and fireproof walls," Caslin said.
She cannot afford those changes right now.
"I'm really devastated that the city would go to this measure, especially since they just contacted us in September. They haven't given us a chance to correct the problems," she said.
"Closing this down is going to do me a lot of harm because it's going to throw me out into an infested world that I'm not prepared to be into right now," Thompson said.
City officials said they support New Deliverance's mission, but they want everyone to be safe, so the residents will have to go.
If you would like to help these 29 people keep their home, Caslin would love to hear from you. You can reach her at 713-728-8288. The folks at the church said this is especially tough because the holidays are right around the corner.
Didn't find what you were looking for?
All content © Copyright 2000 - 2014 Fox Television Stations, Inc. and Worldnow. All Rights Reserved.
Privacy Policy | New Terms of Service What's new | Ad Choices


text:
Prices and availability are subject to change from the time and date that you print this page.
9/15/2014 9:08:31 PM. For Customer Service, please call 800.933.9904
- 200-thread count
- Because multiple colors and stamps are used to create the final design, variance in color and pattern will occur with each piece
- Crib Skirt, Fitted Sheet: 100% cotton percale
- Crib Quilt: Shell is 100% cotton voile (super soft and lightweight); Filling is 100% cotton
- Machine wash cold, gentle cycle, tumble dry low; do not bleach or dry clean
- Coordinating curtain panels also available
- Available in Girls Bedding
Details, details
Show 'em what you're made of
Care instructions
Extras! Extras!
At The Land of Nod, nothing is more important to us than providing safe, high-quality products to you and your family. We believe that kids' products should be able to handle everything kids throw their way (literally and figuratively). That's why all of our products have an 18-year quality guarantee. And, hopefully, your kids will no longer be sleeping in bunk beds by then.
Who's there?
Ear who?
Ear you are, I've been looking everywhere!


text:
Looks like the HTC EVO 4G is out of stock across the country right now. That means decent sales for Sprint, but some annoyance for those who were holding off on ordering the device. [BGR]
HTC EVO 4G Sold Out
Pending approval Rosa Golijan
Filed to: Sprint 6/08/10 2:28pm 6/08/10 2:28pm


text:
We've added an online promo code to your cart. Hold something for pickup, and the code will be applied to your rental without you having to enter it.
My Account
Log Out
Log In
Suggested for You:
Find a Box:
Browse inside all boxes near:
Blu-ray™ Discs won't play on standard DVD players. If your player's compatible, it'll most likely have a Blu-ray™ logo on it. You can learn more about Blu-ray™ here.
Pick up your rentals from one of over 36,000 Redbox locations nationwide.
You've already got 5 items in your shopping cart, so there's no room to reserve another one. If you'd like, you can take something out of your cart to make room for this one.
Click Here » Watch a 10 Minute Preview!
Click Here » Watch a 10 Minute Preview!
Successful newlyweds become the object of a powerful Voodoo Priest who exacts revenge for his scorned daughter.
Rated R by the Motion Picture Association of America for some language.
characters left
Stay in Touch
Preview & reserve movies! Get the app:
At Redbox.com
Customer Service
My Stuff
© 2013, Redbox Automated Retail, LLC. All rights reserved. REDBOX and OUTERWALL and their associated logos are trademarks of Redbox Automated Retail, LLC or its affiliates.Use of this service and this website constitutes acceptance of our Rental Terms, Rewards Terms, Terms of Use and Privacy Policy.


text:
Categories > Celebrities > My Chemical Romance > Black n' Red
Chapter 100 Reviews
im like wide awake, and icant sleep so heres a chapter :)
I couldnt eat. I just wanna see Frankie. I cant help it. My mind is always on him. I never felt like this for a guy ever. But hes gay. He cant be mine. Not now. Not ever. My heart breaks of that thought.
"Hey Amber?" I asked her.
She was stuffing her mouth with a sandwich. She gulps it down and clears her throat.
"How well do you know Frankie?"
"Very. I also know Mikey a lot. If you know what I mean." she said nudging me.
I gasped "NO!" I said shocked "I mean I dont-"
"Like Mikey huh? I get it ok." Amber said with a giggle.
It was quiet. I really dont like the quiet. Then it gets awkward.
"Arent you gonna eat?" Amber asks me looking at my chocolate.
"Want it?" I asked her handing her my chocolate.
I put it on her tray and headed for my locker. I turned back and saw her eating the chocolate. I giggled to myself and continued walking. I see Frankie sitting on the bleachers.
"Hi Frankie!"
He looks up at me.
"Hi Violet, whats up?"
"I was heading to my locker, but then I saw you sitting alone." I paused and looked at the ground and then back at him, "I just thought you can use some company."
I waited for a response.
"Be my guest." he said with a smile.
I sat next to him again in silence.
"Um so what are you doing?" vI asked him.
"Just watching the school," he paused "wondering where I fit in."
I noticed a hint of sadness in his eyes.
"Dont worry, I know how that feels, youll fit in eventually."
"Thanks. So youre friends with Amber?"
"Yeah, shes a nice girl."
"Super nice, shes a friend you can turn to when youre sad, the kind of friend you can tell a secret to and she wont go around telling anyone."
"You mean a true friend?"
"Yeah, theyre arent many of those out here."
We sat there watching the cheerleaders practice. All of them practice their routine except one. The captain, Amy Green. She has a perfecr figure, with her long golden blonde hair. Only one flaw. Shes a slut.
Frankie giggles.
"Whats so funny?" I asked him.
"You look so lost, like a puppy."
I found myself giggling louder, "Im sorry, Im just thinking."
Amy looks at us. I see her tell her girls something and heads our direction.
"Shit!" Frankie yells.
"Whats wrong?" I asked so worried.
"We need to g-"
"Hey!" Amy says to Frankie.
"Um...hi Amy..."
Amy looks at me. Up and down.
"Ugh. Whos this?"
"Um...this is Violet..." Frankie said sounding nervous.
"Oh." she said sounding disgusted.
Then she turns to Frankie and puts her hand on his shoulder.
"Why dont yoy come down and watch us practice?" she asked him.
"Um...I cant..."
"Why?" she asked him sounding mad.
"Um..." Frankie looked scared.
"Cause hes helping me study." I jumped in.
"Oh yeah?" she challeged me.
"Then why were you guys laughing?"
"So what? We cant laugh anymore!?"
She stared at me. She tossed her hair back and walked away with her hips swaying.
"Thank you so much Violet!" he said sounding relieved.
"Can I ask you something?"
"Yes, anything."
"Do you like Amy Green?"
"No! Oh God no!" he said sounding shocked.
"Then why do you get nervous when she talks to you or touches you?"
"I feel uncomfortable..."
"Is it because shes trying to get at you?"
"Yeah its weird."
"Frankie you should just tell her."
"No way!" he yelled, "its embarrassing!"
"But its who you are!"
"I cant...I-" Frankie paused and looked down.
"Whats wrong?"
"I feel dizzy..." he said looking like hes gonna barf. "I gotta go!"
He ran to the nearest trash can and threw up.


text:
Get Undone
Written on September 22, 2010 at 9:33 am , by Fitness Magazine
Changing of seasons brings a changing of trends. My favorite for fall? The 90s grunge look shown by designers like Alexander Wang (Fall 2010) and worn by celebrities including Emma Roberts and Drew Barrymore. The undone-on-purpose look is classic and edgy; that's exactly what I love about it! Unlike most extravagant styles done on the runway, this one is doable at home (and is super-easy to execute after a workout). To get this look you'll need a brown eye shadow with orangey tones, like Urban Decay Deluxe Eye Shadow in Heat, and an eyeliner that smudges easy, like Maybelline Line Express Eyeliner in Ebony Black, which comes with a built in smudging end. Dust a bit of tawny bronzer on cheekbones and finish with a matte lip balm. Bonus: This is a perfect opportunity to give your hair a break and let it dry naturally. Would you try the messy-chic look?
-Kari LaPrade, beauty intern
Categories: Beauty On the Go, Weird-But-Works Wednesday | Tags: Beauty, Fitness Magazine, grunge, On-the-go, undone
No Comments


text:
Woodworker's Journal
Most recently, however, he began building things for his house after getting married about 12 years ago; friends saw them and asked him to build things for them; then it became friends of friends -- and it went from there. "I rarely build things for myself anymore," Jason said, even though woodworking is still not his "day job."
Instead, Jason works as a polymer chemist, which he says gives him a unique insight into the finishing aspect of woodworking. "I don't make finishes, but the chemistry is the same," he said. "I kind of delve into the science behind it." He says he's finding that newer waterborne finishes are an alternative to lacquer that they weren't even seven or eight years ago. "Now my number one finish is General Finishes Enduro-Var. Its ease of use rivals any lacquer, at least in my hands it does," he said. "I'm not trying to use green finishes, I just think they're becoming more durable."
As for his actual woodworking pieces, Jason says he's best known for his unusual chairs. "I particularly enjoy building chairs. In my opinion, all aspects of woodworking go into it: proportion, design, functionality. It has to look good, but you have to be able to sit in it."
One of his chairs, "Curvis Sedis II," is particularly memorable. It's got complex joinery of interlocking dovetails, as well as spline dovetails, a covered seat that's tapered to the edge, and a frame made of bent laminations. "It was a real test of seeing how far I could go, and push the limits of what I could do, to make it. I was sort of challenging myself, I guess," Jason said.
Another chair in Jason's work has a coopered seat, instead of steambent. "I wanted the grain to run perpendicular to the curve," he said. "Right now, I'm really into the coopering technique, because not many people do it."
As for other techniques, Jason said, "I like bent laminations; I like hand-cut dovetails -- I like the way they look." Also, he said, "It's taken me about 12 years to appreciate hand tools in a major way. I'll use a power tool if it will do the job better, but I can at least now appreciate when a hand tool is the appropriate choice."
For wood choices, "I like to use local woods, but it's not my main thing," Jason said. He just finished a desk made from a spalted pecan that fell near him, but the desk also has a walnut top and turned wenge feet, while his dad's position as a groundskeeper at a golf course on the Texas Gulf Coast has meant Jason had access to some mesquite that had to be cut down. He's also currently working on a piece with boards he sawed and air dried for three and a half years which came from an elm tree in his front yard that died. But, he said, "We don't have a substitute for mahogany that grows in Texas."
Most of Jason's pieces have a contemporary style, largely because "I do not like to copy anything," he said. When potential customers approach him about building something they've seen in a furniture store, "If they're happy with those there, I tell 'em to go buy it. It will be two to three times more if I build it. Some people don't understand how much work goes into making a handmade piece."


text:
Top Hotel Room Service
Loews Miami Beach Hotel
Miami, Florida
At this oceanfront gem in the heart of South Beach, room service is like its very own restaurant. Master sushi chef Osamu "Fuji" Fujita whips up specialties such as the Hurricane (spicy scallop and yucca, topped with tuna and served with yuzu miso), and signature items from three of the hotel's restaurants are available for in-room dining. Insider tip: Buy a bottle and a mixologist from the hotel bar will mix a freshly muddled cocktail, like the Miami Mojito, at your doorstep. Rooms, from $280; 305-604-5442; loewshotels.com.


text:
42 U.S. Code § 290cc–23 - Requirement of matching funds
(a) In general
The Secretary may not make payments under section 290cc–21 of this title unless, with respect to the costs of providing services pursuant to section 290cc–22 of this title, the State involved agrees to make available, directly or through donations from public or private entities, non-Federal contributions toward such costs in an amount that is not less than $1 for each $3 of Federal funds provided in such payments.
(b) Determination of amount
Non-Federal contributions required in subsection (a) of this section may be in cash or in kind, fairly evaluated, including plant, equipment, or services. Amounts provided by the Federal Government, or services assisted or subsidized to any significant extent by the Federal Government, shall not be included in determining the amount of such non-Federal contributions.
(c) Limitation regarding grants by States
The Secretary may not make payments under section 290cc–21 of this title unless the State involved agrees that the State will not require the entities to which grants are provided pursuant to section 290cc–22 (a) of this title to provide non-Federal contributions in excess of the non-Federal contributions described in subsection (a) of this section.
Source(July 1, 1944, ch. 373, title V, § 523, as added Pub. L. 100–77, title VI, § 611(3),July 22, 1987, 101 Stat. 517; amended Pub. L. 101–645, title V, § 511,Nov. 29, 1990, 104 Stat. 4728.)
Prior Provisions
A prior section 523 of act July 1, 1944, was renumbered section 544 by section 611(2) ofPub. L. 100–77and is classified to section 290dd–3 of this title.
1990—Pub. L. 101–645amended section generally, substituting present provisions for provisions which related to: in subsec. (a), general requirements; and in subsec. (b), determination of amount of non-Federal contribution.
The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.
The most recent Classification Table update that we have noticed was Tuesday, August 13, 2013
An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.
|Description of Change
|Session Year
|Public Law
|Statutes at Large
LII has no control over and does not endorse any external Internet site that contains links to or references LII.


text:
The Doc never fails…(A firsthand view: posts from Doc Johnson fans – post #1, by Kurt Winkler)
21 Oct
A firsthand view: posts from Doc Johnson fans – post #1
The Doc never fails…
When Doc Johnson posted that they were looking for a regular guy like me to write a guest post for the Doc, I immediately jumped at the opportunity.
It's a bold statement, but I'll make it anyway: Doc Johnson makes the absolute best sex toys on the planet. Have you seen how often they bring out beautiful, innovative, and functional products, or entered one of their great contests (ie. the Fun with Doc, a contest in which users had to record themselves using a DJ sex toy as something other than its actual purpose)? My wife and I won two great toys from the 35 Days of Doc contest. We are very happy with them, as with all the other products we have ordered/purchased through the years. I recommend the Doc to everyone I know, and I mean everyone! Except for the kids, that is.
Years of greatness aside, what excites me most about Doc Johnson recently is its latest collaborations with adult superstars like Sasha Grey and Faye Reagan—my two favorite fantasies. While I'll probably never get to meet these two beauties personally, owning toys by them is the next best thing.
So, to sum up my guest post, I am extremely happy and pleased with all the products and services the Doc has to offer, as well as being excited to see what kind of products they will come out with down the road. I'm sure that I will be buying Doc Johnson for myself, my wife, and even my close friends (TRUST ME; THEY ARE ALWAYS SURPRISED) for years to come! I could never buy from another manufacturer—with Doc Johnson, I am a completely satisfied customer.
Thank you, Doc, for all your years of service! Here's to many more!
Kurt Winkler
PS- If Sasha or Faye ever come to your offices, please them know that their #1 fan lives in Windsor, ON Canada!


text:
Audiology: Referral Directory
Physician ContactsAmy C. Brenski, M.D.
Key Contacts
Krystal Atkins, CCC-A
Paige Bailey Wahl, Au.D., CCC-A
Bethany Baumgart, Au.D., CCC-A
Kimberly Chamberlain, Au.D., CCC-A
Tiana Delgado, MS, CFY-A
Bill Even, MA, CCC-A
Shelly Jones, Au.D.
Pamela Kruger, Au.D.
Laurie Kwon, Au.D., CCC-A
Cherysse Lanns, Au.D., CCC-A
April Liehr Townsley, MA, CCC-A
Teriann Scheets, MS, CCC-A
Melanie Shellburg, Au.D., CCC-A
Johanna Whitson, MS, CCC-A
Description of Services
Specialized audiological evaluations through various types of hearing tests are provided for the assessment of infants, children and special populations. Audiology services are provided by certified and licensed clinical audiologists who specialize in pediatric assessment.
Physician Contact
A wide variety of procedures are available to assess a child's ability to hear and process sounds at various developmental stages, including:
- Audiological consultation
- Behavioral hearing evaluation
- Visual reinforcement audiometry
- Conditioned play audiometry
- Tympanometry/acoustic reflex
- Otoacoustic emissions
- Auditory brainstem response (including bone conduction and tone burst ABRs)
- Screening auditory brainstem response for infants 0-6 months of age.
Information for referral sources:
- Patient instructions for specific tests will be provided when the appointment is scheduled.
- Diagnosis, evaluation and recommended treatment information is provided promptly to the referring physician.
- For questions or urgent messages, call 214-456-2386.
Please provide the following when calling to schedule a patient for a diagnostic examination:
- Patient name and date of birth
- Insurance/referral information
- Referring/primary care physician name and phone number
Why Children's Medical Center?
- Diagnosis and intervention are provided by a multidisciplinary team consisting of an audiologist, speech-language pathologist, parents, teachers and, on many occasions, psychologists.
- A comprehensive battery of tests are given by an audiologist and a speech-language pathologist with extensive experience in assessing auditory disorders. Intervention may include therapy that can be provided by Children's. The audiologist and the speech-language pathologist develop recommendations for the child's educational program and home environment.
- Pediatric audiologists at Children's are skilled in evaluation of newborns and use state-of-the art procedures to provide comprehensive diagnostic evaluation of infants at risk for hearing loss.


text:
Why we love it!
Who else loves it!
Best in Beauty - Best Pore Perfector, Woman and Home, 2011
Shortlisted - Best New Cosmetic Product, The UK Beauty Awards, 2011
Best Makeup Primer, Company Beauty Awards, 2012
Best New Make-up Product: Face - Prestige - FINALIST, CEW Beauty Awards, 2012
Beauty Bible Award Winner, Anti-ageing Beauty Bible Award, 2012
Best Pore Minimising Primer, Social and Personal, 2012
Best Porefector, Woman and Home Beauty awards, 2013
How to apply
Download the illustrated step-by-step lesson on how to apply. view instructions
22.0 mL / 0.75 US fl. oz.
Beauty tip
Apply the POREfessional from the center of the face outward by patting lightly with fingertips...pay particular attention to the T-zone area. Keep it in your bag for touch-ups during the day.view ingredients


text:
Health - Class/Workshop
Tuesdays, September 11, 2012 - December 22, 2012
Flowforms Yoga Center
195 Lake Ave
Worcester, MA 01604
Google Maps - MapQuest
Gentle combines gentle stretching, restorative poses, yogic breathing, relaxation and meditation. Perfect for those who want to unwind, reduce anxiety and stress or have physical concerns or injuries. Cultivate self-awareness and self-love. By getting to know and trust your own body each student will find their perfect level of practice on any given day. 75 minutes
Suggested Audiences: College, Adult, Elders
Website: http://www.FlowformsYoga.com
E-mail: firstname.lastname@example.com
Phone: 508-752-4700
Last Modified: September 6, 2012 at 6:10 PM
Add/Suggest Event | Edit Your Events |
Powered by the Social Web - Bringing people together through Events, Places, & Common Interests


text:
Join the J Cole newsletter for the latest news and info.
Subscribe Now!
Upload your J. Cole concert photos here!
Think you could be a double? See what others think...
Grab a shot with J. Cole and share it online!
Of all those fat burners available on the market place, Phen375 is considered as one of the best. Its value is greatly enhanced by the high-quality...
Sign in for community access log in
Not a member? Sign up